LIPT - Liraglutide in Polycystic Ovary Syndrome

NCT02073929 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can affect blood clotting in women with polycystic ovary syndrome.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 72 people

Who can join Ages 18–60 · female only

Timeline Started 2014-03 · est. completion 2015-12

Where 3 sites · Denmark

What this study is testing ClinicalTrials.gov NCT02073929 ↗

Description as written by the study sponsor.

Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.

Treatments tested

Liraglutide for 26 weeks Drug

GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
placebo Drug

Placebo s.c. daily for 26 weeks

Main thing measured	Change in Endogenous Thrombin Potential (ETP)
Sponsor	Jens Faber
Conditions studied	Polycystic Ovary Syndrome, Cardiovascular Disease
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02073929 ↗